HEALTH OF WOMAN. 2016.9(115):94–98 
 

The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy* 
 

Mahmud Zakut, Emad Islam, Mazen Abukamar, Osama Abugassa, Joseph Panzer, Daniel De Wolf

Department of pediatric cardiology, Hospital at Ghent University, De Pintelaan 185, 9000 Ghent, Belgium

Department of pediatric cardiology, Children's hospital Abd al Aziz al Rantisi, Gaza, Palestine

Department of public health, al Quds University, Gaza, Palestine

Royal healthcare trust, London, UK

Congenital heart disease is the most frequent form of congenital anomaly in newborn infants and accounts for more than a quarter of all serious congenital afflictions worldwide. A genetic etiology is identified in <20% of cases of congenital heart defects, and in most cases the etiology remains a mystery. In the context of the health burden caused by congenital heart disease, the contribution of non-inherited risk factors is important especially if it turns out to be caused by a drug which can be avoided during pregnancy. We sought to determine whether maternal dydrogesterone treatment in early pregnancy is associated with congenital heart disease in the infant. We conducted a retrospective case–control study of birth defects and associated risk factors. Data were obtained and compared between 202 children born with congenital heart disease and a control group consisting of 200 children. All children were born in the period of 2010–2013. Dydrogesterone exposure was defined as any reported use during the first trimester of pregnancy. Exclusion criteria included stillbirths, children with chromosomal abnormalities and infants of mothers with chronic medical illnesses, e.g., diabetes. Binary logistic regression analyses were used to analyze the data and attempt to identify a causal relationship between drug exposure and congenital heart disease. Mothers of children born with congenital heart disease received more dydrogesterone during first trimester of pregnancy than mothers of children in the control group [adjusted odds ratio 2.71; (95 % CI 1.54–4.24); P = 0.001]. We identified a positive association between dydrogesterone usage during early pregnancy and congenital heart disease in the offspring. Nevertheless, further studies are needed to confirm these results.

Key words: Congenital heart disease, Dydrogesterone, Pregnancy.

REFERENCES

1. Bracken MD, Holford TR, White C et al. 1978. Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 7:309. https://doi.org/10.1093/ije/7.4.309; PMid:744667

2. Chard T. 1991. Frequency of implantation and early pregnancy loss in natural cycles. Baillieres Clin Obstet Gynaecol 5:179–189. https://doi.org/10.1016/S0950-3552(05)80077-X

3. Greenberg G, Inman WHW, Weatherall JAC et al. 1977. Maternal drug histories and congenital abnormalities. BMJ 2:853. https://doi.org/10.1136/bmj.2.6091.853; PMid:922327 PMCid:PMC1631672

4. Harlap S, Prywes R, Davies AM. 1975. Birth defects and estrogens and progesterones in pregnancy. Lancet 1:682. https://doi.org/10.1016/S0140-6736(75)91784-5

5. Harlap S, Shiono PH, Ramcharan S. 1985. Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertil 30:39. PMid:2865223

6. Heinonen OP, Slone D, Monson RR et al. 1976. Cardiovascular birth defects in antenatal exposure to female sex hormones. N Engl J Med 296:67. https://doi.org/10.1056/NEJM197701132960202; PMid:830309

7. Heinonen OP, Slone D, Shapiro S. 1979. Birth defects and drugs in pregnancy. Littleton Teratol 20(3):487–488.

8. Hook EB. 1994. Cardiovascular birth defects and prenatal exposure to female sex hormones: a reevaluation of data from a large prospective study. Teratology 49:162. https://doi.org/10.1002/tera.1420490303; PMid:8059421

9. Janerich DT, Dugan JM, Standfast SJ et al. 1977. Congenital heart disease and prenatal exposure to exogenous sex hormones. BMJ 1:1058. https://doi.org/10.1136/bmj.1.6068.1058; PMid:858045 PMCid:PMC1606075

10. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL. 2007. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115(23):2995–3014. https://doi.org/10.1161/CIRCULATIONAHA.106.183216; PMid:17519397

11. Kline J. 1989. Conception to birth—epidemiology of prenatal development. Monographs in epidemiology and biostatistics, vol 14. Oxford University Press, Oxford. PMid:2500945

12. Kullander S, Kallen B. 1976. A prospective study of drugs and pregnancy. Acta Obstet Gynecol Scand 55:221. https://doi.org/10.3109/00016347609156795; https://doi.org/10.3109/00016347609158500; https://doi.org/10.3109/00016347609156779; https://doi.org/10.3109/00016347609156917; PMid:936986

13. Levy EP, Cohen A, Fraser FC. 1973. Hormone treatment during pregnancy and congenital heart disease. Lancet 1:611. https://doi.org/10.1016/S0140-6736(73)90762-9

14. Lewallen S. 1998. Epidemiology in practice: case–control studies. Community Eye Health 11(28):57–58. PMid:17492047 PMCid:PMC1706071

15. Michaelis J, Michaelis H, Gluck E et al. 1983. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 27:57. https://doi.org/10.1002/tera.1420270109; PMid:6845218

16. Mitchell SC, Korones SB, Berendes HW. 1971. Congenital heart disease in 56,109 births. Incidence and natural history. Circulation 43:323–332. https://doi.org/10.1161/01.CIR.43.3.323 
PMid:5102136

17. Nora JJ, Nora AH, Blum J et al. 1978. Exogenous progestogen and estrogen implicated in birth defects. JAMA 240:837. https://doi.org/10.1001/jama.1978.03290090031012; https://doi.org/10.1001/jama.240.9.837; PMid:671728

18. Richards AA, Santos LJ, Nichols HA, Crider BP, Elder FF, Hauser NS, Zinn AR, Garg V. 2008. Cryptic chromosomal abnormalities identified in children with congenital heart disease. Pediatr Res 64(4):358–363. https://doi.org/10.1203/PDR.0b013e31818095d0; PMid:18535492

19. Royal College of General Practitioners. 1976. The outcome of pregnancy in former oral contraceptive users. Br J Obstet Gynaecol 83:608. https://doi.org/10.1111/j.1471-0528.1976.tb00897.x; PMid:952791

20. Savolainen E, Saksela E, Saxen L. 1981. Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 140:521. https://doi.org/10.1016/0002-9378(81)90227-1

21. Stirrat GM. 1990. Recurrent miscarriage. Lancet 336:673–675. https://doi.org/10.1016/0140-6736(90)92159-F

22. Torfs C, Milkovich L, Van Den Berg BJ. 1981. The relationship between hormonal pregnancy tests and congenital abnormalities: a prospective study. Am J Epidemiol 113:563. https://doi.org/10.1093/oxfordjournals.aje.a113133; PMid:7194580

23. Varma TR, Morsman J. 1982. Evaluation of the early use of proluton-depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet 20:13. https://doi.org/10.1016/0020-7292(82)90039-X

24. Vessey MP. 1979. Outcome of pregnancy in women using different methods of contraception. Br J Obstet Gynecol 86:548. https://doi.org/10.1111/j.1471-0528.1979.tb10808.x; PMid:476021

25. Wilcox AJ, Weinberg CR, O’Connor JF et al. 1988. Incidence of early loss of pregnancy. N Engl J Med 319:189–194. https://doi.org/10.1056/NEJM198807283190401; PMid:3393170

26. Wiseman RA, Dodds-Smith IC. 1984. Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data. Teratology 30:359. https://doi.org/10.1002/tera.1420300308; PMid:6240131

27. Zaqout M, Aslem ES, Oweida FS, De Wolf D. 2014. Prevalence of congenital heart disease among Palestinian children born in the Gaza Strip. Cardiol Young 24(5):905–909. https://doi.org/10.1017/S1047951113001418; PMid:24047755